AN2 Therapeutics COO Eizen sells 2,826 shares

The listed RSU balances vest in annual installments over four years, subject to Joshua M. Eizen's continuous service.

Available on EDGAR 11/06/2026 - 06:24 PM EST Accepted by SEC EDGAR 11/06/2026 - 06:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. Chief Operating Officer and Chief Legal Officer Joshua M. Eizen sold 2,826 shares of common stock at $4.22 per share on November 5, 2026, to satisfy tax withholding obligations arising from RSU vesting on November 4, 2026. No Rule 10b5-1 plan is reported. His reported post-transaction total was 207,546 shares; the footnotes say it includes RSU balances and 3,818 shares purchased under the issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.

Insider Trade Summary

Net Seller: 2,826 shares

Net Sell 1 txn

Insider Eizen Joshua M

Role See Remarks

Sold 2,826 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	2,826	$4.22	$12K

Holdings After Transaction: Common Stock — 207,546 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2026.
2. F2. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
3. F3. Reflects the adjusted total which includes the purchase of 3,818 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.

Key Figures

Common shares sold: 2,826 shares Sale price: $4.22 per share Post-transaction total: 207,546 shares +5 more

8 metrics

Common shares sold 2,826 shares Sale on November 5, 2026

Sale price $4.22 per share Sale on November 5, 2026

Post-transaction total 207,546 shares Reported after the November 5, 2026 sale

Employee Stock Purchase Plan purchase 3,818 shares Purchased on September 30, 2026; included in the reported post-transaction total

RSUs 30,000 RSUs One quarter vests annually over four years from January 1, 2024, subject to continuous service

RSUs 31,500 RSUs One quarter vests annually over four years from November 4, 2024, subject to continuous service

RSUs 58,500 RSUs One quarter vests annually over four years from January 1, 2025, subject to continuous service

RSUs 50,000 RSUs One quarter vests annually over four years from January 1, 2026, subject to continuous service

Key Terms

Restricted Stock Units, tax withholding obligations, 2022 Employee Stock Purchase Plan

3 terms

Restricted Stock Units financial

"vesting of Restricted Stock Units (RSUs) on November 4, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy tax withholding obligations arising from the vesting"

2022 Employee Stock Purchase Plan financial

"under the Issuer's 2022 Employee Stock Purchase Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANTX shares did Joshua M. Eizen sell, and at what price?

Joshua M. Eizen sold 2,826 shares at $4.22 per share on November 5, 2026. The sale was to satisfy tax withholding obligations arising from RSUs vesting on November 4, 2026; no Rule 10b5-1 plan is reported.

What was Joshua M. Eizen's reported ANTX share total after the sale?

His reported post-transaction total was 207,546 shares. The footnotes say it includes RSU balances and 3,818 shares purchased under AN2 Therapeutics' 2022 Employee Stock Purchase Plan on September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eizen Joshua M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		S		2,826(1)	D	$4.22	207,546(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2026.

2. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.

3. Reflects the adjusted total which includes the purchase of 3,818 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.

Remarks:

Chief Operating Officer and Chief Legal Officer

	/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)